Healthcare & Biotech

SHERIDAN, WYOMING - March 21, 2026 - HubSpot has published a new guide comparing Claude and ChatGPT for marketers, focusing on three practical buying criteria: pricing, integrations, and use cases. The article frames AI model selection as an operational decision rather than a purely technical one, aimed at helping marketing teams choose the right large language model for day-to-day work. For business users, that matters because LLM choice can affect tool compatibility, workflow design, and budget planning across content and campaign functions.

SHERIDAN, WYOMING - March 31, 2026 - Early-stage medtech companies could regain a key non-dilutive funding route in 2026 after the Senate passed legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, reducing uncertainty that has persisted since the programs' authorization lapsed on September 30, 2025. AdvaMed said the Senate action restores momentum for grants that support early research and development at startups and small manufacturers, and it urged the House of Representatives to move quickly on passage. The association framed the programs as an important bridge for companies that struggle to finance next-generation device development before products reach patients or later-stage commercial milestones.

SHERIDAN, WYOMING - March 31, 2026 - Health organizations planning 2026 research participation in Europe gain a new route to influence project design, allocate in-kind resources, and support proposals without taking on full private-member status in the Innovative Health Initiative. MedTech Europe points to an 11 February 2026 webinar hosted by the IHI Office, focused on the contributing partner category for organizations that are not affiliated with an IHI private industry member, as well as organizations affiliated with a private member that need to understand how contributing partners can support proposals. The session is positioned around practical participation questions rather than broad program promotion, including eligibility, application steps, contribution rules, and common mistakes.

SHERIDAN, WYOMING - March 31, 2026 - European hospitals evaluating 2026 imaging, intervention, and workforce plans now have a new validation pathway for AI-assisted neurovascular and oncology procedures as the SHERPA consortium starts seven clinical studies focused on workflow automation, precision support, and staff-pressure reduction in minimally invasive care. The four-year project has a total budget of EUR 21.5 million, is coordinated by Philips, and is co-funded by the EU Innovative Health Initiative and industry partners. Its work targets minimally invasive treatment workflows for brain aneurysms, liver tumors, and lung biopsy settings where specialized expertise is limited and procedure complexity is high.

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

SHERIDAN, WYOMING - December 30, 2025 - ALS Northwest says it increased its financial investment in ALS research throughout 2025, expanding support for new approaches in treatment, prevention, and scientific understanding while joining a multi-organization funding initiative intended to strengthen the overall research pipeline.

Research investment strategy and portfolio focus

ALS Northwest framed its 2025 approach as a scaled-up commitment to research designed to accelerate innovation in amyotrophic lateral sclerosis (ALS). The organization said its efforts span multiple stages of scientific discovery, with an emphasis on enabling new approaches that could move the field forward. For research stakeholders, the operational question is not only how much is invested, but how efficiently funding is converted into validated findings, new targets, and ultimately clinical progress.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.

SHERIDAN, WYOMING - December 19, 2025 - Bristol Myers Squibb (BMS) has struck a potential $1B-plus partnership with Harbour BioMed to collaborate on next-generation multi-specific antibody programs, underscoring how China-based innovation is increasingly shaping global biologics dealmaking.

Deal scope and economics in brief
BMS will pay $90 million upfront to work with Harbour on developing and advancing multi-specific antibody therapies, with additional development and commercial milestones that could total up to $1.035 billion. The partners did not disclose how many programs are covered, nor did they specify initial targets, indications, or therapeutic areas.

For business development teams and portfolio planners, the structure reflects a familiar "platform-plus-programs" model: BMS buys early discovery leverage and optionality, while Harbour positions itself for milestone upside and downstream royalties if programs progress.

SHERIDAN, WYOMING - December 19, 2025 - Voyager Therapeutics is laying off 30 employees after partner Novartis discontinued two undisclosed discovery-stage programs under the companies' gene therapy collaboration, underscoring how quickly platform-driven R&D bets can be reprioritized even inside marquee pharma partnerships.

Commercial partnerships can shift overnight
Voyager disclosed last month that Novartis had stepped away from two early programs tied to their ongoing relationship, without naming the assets or detailing the rationale. The biotech framed the change as manageable, stating that Novartis' decision will "not impact Voyager's cash runway guidance." Still, the workforce reduction signals that operational resets often follow partnership scope changes-especially when programs are preclinical and the near-term value is concentrated in a smaller set of advancing assets.

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.